Xi Hu1, Fan Xia2, Jiyoung Lee2, Fangyuan Li2,3, Xiaoyang Lu1, Xiaozhen Zhuo4, Guangjun Nie5,6, Daishun Ling2,3. 1. Department of Clinical Pharmacy Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou 310003 China. 2. Institute of Pharmaceutics Zhejiang Province Key Laboratory of Anti-Cancer Drug Research Hangzhou Institute of Innovative Medicine College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 China. 3. Key Laboratory of Biomedical Engineering of the Ministry of Education College of Biomedical Engineering & Instrument Science Zhejiang University Hangzhou 310058 China. 4. Department of Cardiology the First Affiliated Hospital Xi'an Jiaotong University Xi'an 710061 China. 5. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology No.11 Zhongguancun Beiyitiao Beijing 100190 China. 6. GBA Research Innovation Institute for Nanotechnology Guangzhou 510700 China.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide due to its aggressiveness and the challenge to early diagnosis and treatment. In recent decades, nanomaterials have received increasing attention for diagnosis and therapy of PDAC. However, these designs are mainly focused on the macroscopic tumor therapeutic effect, while the crucial nano-bio interactions in the heterogeneous microenvironment of PDAC remain poorly understood. As a result, the majority of potent nanomedicines show limited performance in ameliorating PDAC in clinical translation. Therefore, exploiting the unique nature of the PDAC by detecting potential biomarkers together with a deep understanding of nano-bio interactions that occur in the tumor microenvironment is pivotal to the design of PDAC-tailored effective nanomedicine. This review will introduce tailor-made nanomaterials-enabled laboratory tests and advanced noninvasive imaging technologies for early and accurate diagnosis of PDAC. Moreover, the fabrication of a myriad of tailor-made nanomaterials for various PDAC therapeutic modalities will be reviewed. Furthermore, much preferred theranostic multifunctional nanomaterials for imaging-guided therapies of PDAC will be elaborated. Lastly, the prospects of these nanomaterials in terms of clinical translation and potential breakthroughs will be briefly discussed.
Pancreatic ductal adenocarcinoma (span>n class="Chemical">PDAC) is one of the deadliest cancers worldwide due to its aggressiveness and the challenge to early diagnosis and treatment. In recent decades, nanomaterials have received increasing attention for diagnosis and therapy of PDAC. However, these designs are mainly focused on the macroscopic tumor therapeutic effect, while the crucial nano-bio interactions in the heterogeneous microenvironment of PDAC remain poorly understood. As a result, the majority of potent nanomedicines show limited performance in ameliorating PDAC in clinical translation. Therefore, exploiting the unique nature of the PDAC by detecting potential biomarkers together with a deep understanding of nano-bio interactions that occur in the tumor microenvironment is pivotal to the design of PDAC-tailored effective nanomedicine. This review will introduce tailor-made nanomaterials-enabled laboratory tests and advanced noninvasive imaging technologies for early and accurate diagnosis of PDAC. Moreover, the fabrication of a myriad of tailor-made nanomaterials for various PDAC therapeutic modalities will be reviewed. Furthermore, much preferred theranostic multifunctional nanomaterials for imaging-guided therapies of PDAC will be elaborated. Lastly, the prospects of these nanomaterials in terms of clinical translation and potential breakthroughs will be briefly discussed.
Authors: Andrew H Ko; Noelle LoConte; Margaret A Tempero; Evan J Walker; R Kate Kelley; Stephanie Lewis; Wei-Chou Chang; Emily Kantoff; Michael W Vannier; Daniel V Catenacci; Alan P Venook; Hedy L Kindler Journal: Pancreas Date: 2016-03 Impact factor: 3.327
Authors: Andrea Viale; Piergiorgio Pettazzoni; Costas A Lyssiotis; Haoqiang Ying; Nora Sánchez; Matteo Marchesini; Alessandro Carugo; Tessa Green; Sahil Seth; Virginia Giuliani; Maria Kost-Alimova; Florian Muller; Simona Colla; Luigi Nezi; Giannicola Genovese; Angela K Deem; Avnish Kapoor; Wantong Yao; Emanuela Brunetto; Ya'an Kang; Min Yuan; John M Asara; Y Alan Wang; Timothy P Heffernan; Alec C Kimmelman; Huamin Wang; Jason B Fleming; Lewis C Cantley; Ronald A DePinho; Giulio F Draetta Journal: Nature Date: 2014-08-10 Impact factor: 49.962
Authors: Carlos Pérez-Medina; Dalya Abdel-Atti; Jun Tang; Yiming Zhao; Zahi A Fayad; Jason S Lewis; Willem J M Mulder; Thomas Reiner Journal: Nat Commun Date: 2016-06-20 Impact factor: 14.919
Authors: Luman Liu; Prakash G Kshirsagar; Shailendra K Gautam; Mansi Gulati; Emad I Wafa; John C Christiansen; Brianna M White; Surya K Mallapragada; Michael J Wannemuehler; Sushil Kumar; Joyce C Solheim; Surinder K Batra; Aliasger K Salem; Balaji Narasimhan; Maneesh Jain Journal: Theranostics Date: 2022-01-01 Impact factor: 11.600